Benedetta Albieri

Benedetta Albieri

Auto-generated profile, based on publicly available information

Benedetta Albieri

National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 December 2023 in OncoImmunology
Verified
Journal Article
Open access
MNMorten Nielsen
Morten Nielsen
TMTine Monberg
Tine Monberg
VSVibeke Sundvold
Vibeke Sundvold
BABenedetta Albieri
Benedetta Albieri
DHDorrit Hovgaard
Dorrit Hovgaard
Inge MarieInge Marie
Inge Marie
LTX-315 is an oncolytic peptide that elicits both local and systemic immune responses upon intratumoral injection. In the present pilot trial, we treated patients with metastatic soft tissue sarcoma with the combination of LTX-315 and adoptive T-cell therapy using in vitro expanded tumor-infiltrating lymphocytes. Six heavily pretreated patients were included in the trial and treated with LTX-315 of which four patients proceeded to adoptive T-cell therapy. Overall, the treatment was considered safe with only expected and manageable toxicity. The best overall clinical response was stable disease for 208 days, and in this patient, we detected tumor-reactive T cells in the blood that lasted until disease progression. In three patients T-cell reactivity against in silico predicted neoantigens was demonstrated. Additionally, de novo T-cell clones were generated and expanded in the blood following LTX-315 injections. In conclusion, this pilot study provides proof that it is feasible to combine LTX-315 and adoptive T-cell therapy, and that this treatment can induce systemic immune responses that resulted in stabilization of the disease in sarcoma patients with otherwise progressive disease. Further optimization of the treatment protocol is warranted to increase clinical activity. ClinicalTrials.gov Identifier: NCT03725605

1 May 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
ADArianna Draghi
Arianna Draghi
MPMario Presti
Mario Presti
AJAgnete W.P. Jensen
Agnete W.P. Jensen
CCChristopher Chamberlain
Christopher Chamberlain
BABenedetta Albieri
Benedetta Albieri
Marco DoniaMarco Donia
Marco Donia
Purpose: Impaired MHCI-presentation and insensitivity to immune effector molecules are common features of immune checkpoint blockade (ICB)-resistant tumors and can be, respectively, associated with loss of β2 microglobulin (B2M) or impaired IFNγ signaling. Patients with ICB-resistant tumors can respond to alternative immunotherapies, such as infusion of autologous tumor-infiltrating lymphocytes (TIL). CD4+ T cells can exert cytotoxic functions against tumor cells; however, it is unclear whether CD4+ T-cell responses can be exploited to improve the clinical outcomes of patients affected by ICB-resistant tumors. Experimental Design: Here, we exploited CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 gene editing to reproduce immune-resistant tumor phenotypes via gene knockout (KO). To determine the role of cytotoxic CD4+ TILs in ICB-resistant tumors, we investigated CD4+ TIL-mediated cytotoxicity in matched pairs of TILs and autologous melanoma cell lines, used as a model of patient-specific immune-tumor interaction. Around 40% of melanomas constitutively express MHC Class II molecules; hence, melanomas with or without natural constitutive MHC Class II expression (MHCIIconst+ or MHCIIconst−) were used. Results: CD4+ TIL-mediated cytotoxicity was not affected by B2M loss but was dependent on the expression of CIITA. MHCIIconst+ melanomas were killed by tumor-specific CD4+ TILs even in the absence of IFNγ-mediated MHCII upregulation, whereas IFNγ was necessary for CD4+ TIL-mediated cytotoxicity against MHCIIconst- melanomas. Notably, although tumor-specific CD4+ TILs did not kill JAK1KO MHCIIconst- melanomas even after IFNγ stimulation, sensitivity to CD4+ TIL-mediated cytotoxicity was maintained by JAK1KO MHCIIconst+ melanomas. Conclusions: In conclusion, our data indicate that exploiting tumor-specific cytotoxic CD4+ TILs could help overcome resistance to ICB mediated by IFNγ-signaling loss in MHCIIconst+ melanomas. See related commentary by Betof Warner and Luke, p. 3829

20 August 2026 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
LHLyna Haybout
Lyna Haybout
TKTatiana V Kudling
Tatiana V Kudling
JCJames H Clubb
James H Clubb
TMTine Juul Monberg
Tine Juul Monberg
BABenedetta Albieri
Benedetta Albieri
AHAkseli Hemminki
Akseli Hemminki
Background: Metastatic melanoma resistant to immune checkpoint inhibitors remains difficult to treat, and while adoptive tumor-infiltrating lymphocyte (TIL) therapy has shown durable responses, its reliance on lymphodepleting chemotherapy and high-dose interleukin (IL)-2 causes toxicity that may limit patient eligibility. The dual-cytokine-armed oncolytic adenovirus igrelimogene litadenorepvec (TILT-123) was administered with TILs in the TUNINTIL trial (trial registration: NCT04217473 ) in patients with metastatic melanoma resistant to immune checkpoint inhibitors, without lymphodepleting chemotherapy or IL-2 post-conditioning. This study presents a correlative immunological analysis of the phase I TUNINTIL trial evaluating TILT-123 in combination with TIL therapy. Methods: The TUNINTIL trial was a first-in-human, open-label, dose-escalation, multicenter, multinational phase I trial. 17 patients with checkpoint-inhibitor-resistant metastatic melanoma received up to six intratumoral TILT-123 injections followed by TIL infusion, without lymphodepleting chemotherapy or IL-2 post-conditioning. Systemic immune profiling (serum proteomics, flow cytometry, interferon-γ ELISpot assay), intratumoral immune cell–cell profiling (multiplex immunofluorescence, H&E, adenovirus E1a immunohistochemistry), quantitative PCR, and neutralizing antibody responses were assessed at defined time points through the trial, with survival follow-up updated to March 2026. Response criteria were evaluated using Response Evaluation Criteria in Solid Tumors V.1.1 and positron emission tomography-based criteria. Statistical analyses included Kaplan-Meier survival with log-rank tests, Mann-Whitney U tests, Pearson correlation, and receiver operating characteristic/area under the curve analysis for biomarker cut-off determination. Results: Tumor biopsy analyses revealed an early innate immune activation marked by natural killer-cell expansion and cytotoxic gene upregulation, followed by increased intratumoral T-cell infiltration. This occurred without lymphodepleting chemotherapy or post-conditioning IL-2. Intratumoral viral DNA was detectable in a subset of patients. The enrichment of CD27+CD28+ memory-precursor CD8+ T cell was associated with favorable clinical outcomes. Elevated monocytic myeloid-derived suppressor cells and angiogenic/inflammatory cytokines following combination treatment were associated with disease progression, highlighting the role of immunosuppressive myeloid subsets as potential mediators of therapeutic resistance. Additionally, correlative analysis in pooled TILT-123 cohorts identified serum epidermal growth factor as a candidate biomarker for stratifying and monitoring patients. Conclusions: These findings provide mechanistic insights into TILT-123 combined with TIL therapy and propose future directions for biomarker-guided clinical studies. Trial registration number: NCT04217473 .

25 November 2025
Verified
Other
Open access
ADArianna Draghi
Arianna Draghi
MPMario Presti
Mario Presti
AJAgnete W.P. Jensen
Agnete W.P. Jensen
CCChristopher Chamberlain
Christopher Chamberlain
BABenedetta Albieri
Benedetta Albieri
Marco DoniaMarco Donia
Marco Donia
CD4+ TILs from melanoma can exert cytotoxic activity against autologous tumor cells (GFP+TCL#17)

12 May 2023
Verified
Other
Open access
PDF file
ADArianna Draghi
Arianna Draghi
MPMario Presti
Mario Presti
AJAgnete W.P. Jensen
Agnete W.P. Jensen
CCChristopher Chamberlain
Christopher Chamberlain
BABenedetta Albieri
Benedetta Albieri
Marco DoniaMarco Donia
Marco Donia
Supplementary Figures and Tables

16 September 2024
Verified
Other
Open access
ADArianna Draghi
Arianna Draghi
MPMario Presti
Mario Presti
AJAgnete W.P. Jensen
Agnete W.P. Jensen
CCChristopher Chamberlain
Christopher Chamberlain
BABenedetta Albieri
Benedetta Albieri
Marco DoniaMarco Donia
Marco Donia
CD4+ TILs from melanoma can exert cytotoxic activity against autologous tumor cells (GFP+TCL#17)